



## Program

---

### Saturday 2nd August

- 15:00 Registration Opens
- 18:30 Doors Open to Exhibition Hall A
- 19:00 Opening Ceremony  
*Exhibition Hall A*
- Welcome Address:*  
**Lisa Marshall**  
Chair, Organising Committee  
**Robin Poole**  
Congress President
- Welcome Reception*  
*Pan Pacific Atrium*
- 21:00 Registration Closes

## Sunday 3rd August



08:00 Introduction  
**Gordon Letts** (Nitromed, USA)  
Chair of Scientific Program  
Committee and Vice-President of IAIS

### Plenary Session 1

EXHIBITION HALL A

Chair: *S Stimpson* (GlaxoSmithKline, USA)

08:30 IS/01 **SL Kunkel** (University of Michigan  
Medical School, USA)  
The role of chemokines in  
established and novel immunologic  
paradigms

09:15 Poster Session A, Exhibition and  
coffee break

### Symposium 1 - Macrophages and Inflammation

*Organised by the Society for Cytokine, Inflammation and Leukocytes (SCIL)*

BALLROOM A

Chairs: *J Hamilton* (University of Melbourne, Australia)  
& *E Morand* (Monash University, Australia)

10:30 IS/02 **JA Hamilton** (University of Melbourne,  
Australia)  
GM-CSF as a pro-inflammatory  
cytokine

11:10 IS/03 **EF Morand** (Monash University, Australia)  
Macrophage migration inhibitory  
factor (MIF) is a potential  
therapeutic target in inflammation



Sunday 3rd August

11:50 IS/03A **P Hertzog** (Monash University, Australia)  
The role of type 1 interferons in TLR4 responses to LPS

12:30 Lunch, Poster Session A & Exhibition (Exhibition Hall B)  
Lunchtime Seminar (Room 8/15)

## Symposium 2 - Matrix Metalloproteinases

Organised by The Canadian Arthritis Network (CAN)

sponsored by Pfizer, Inc

### BALLROOM B

*Chairs: A R Poole* (Shriners Hospital for Children, Canada)  
& *C Overall* (University of British Columbia, Canada)

10:30 IS/04 **Z Werb** (University of California, USA)  
Matrix metalloproteinases: mediators of inflammatory cell functions

11:00 IS/04A **C Overall** (University of British Columbia, Canada)  
New roles for MMPs: chemokine processing terminates inflammation and initiates neuronal apoptosis in HIV dementia

11:30 IS/05 **SJ Weiss** (University of Michigan, USA)  
Proteolytic remodeling of the extra cellular matrix: causes & consequences

12:00 IS/06 **WC Parks** (Washington University School of Medicine, USA)  
Proteolytic regulation of epithelial inflammation and repair

12:30 Lunch, Poster Session A & Exhibition (Exhibition Hall B)  
Lunchtime Seminar (Room 8/15)

Sunday 3rd August



## Symposium 3 - Anti-inflammatory Mechanisms

Organised by the British Inflammation Research Association (BIRAs)

BALLROOM C

*Chairs: I Adcock (NHLI, UK) and N Boughton-Smith (AstraZeneca, UK)*

*Presentation IS/07 is now being presented as a poster in Focus Session 2*

- 10:30 IS/08 **GP Chrousos (NIH, USA)**  
Role of the central nervous system and the hypothalamic-pituitary-adrenal (HPA) axis in inflammation
- 11:10 IS/09 **DW Gilroy (William Harvey Research Institute, UK)**  
Endogenous control of acute inflammation - the role of prostaglandins in mediating inflammatory resolution
- 11:50 IS/10 **M Braddock (AstraZeneca, UK)**  
Interleukin-1 as a therapeutic target: opportunities for inflammatory disease
- 12:30 Lunch, Poster Session A & Exhibition (Exhibition Hall B)  
Lunchtime Seminar (Room 8/15)

### Lunchtime Seminar

*Sponsored by Source Precision Medicine*

MEETING ROOM 8/15

- 12:40 Src/1 **M P Bevilacqua (Source Precision Medicine, USA)**  
Use of high precision gene expression to track inflammatory diseases and therapeutic response



Sunday 3rd August

---

## Focus Session 1 - Targeted Drug Delivery

MEETING ROOM 11

*Chairs: V Muzykantov (University of Pennsylvania Medical Center, USA) and J Kopecek (University of Utah, USA)*

- 14:15 IS/11 **VR Muzykantov (University of Pennsylvania Medical Center, USA)**  
Targeting of antioxidants to adhesion molecules
- 14:45 IS/12 **JR Lindner (University of Virginia Medical Center, USA)**  
Targeting and visualizing inflammation
- 15:15 Refreshments and exhibition (Exhibition Hall B)
- 15:45 IS/13 **J Kopecek (University of Utah, USA)**  
Targeting of drugs to cancerous and inflamed tissues
- 16:15 IS/14 **PD Senter (Seattle Genetics, USA)**  
Development of potent monoclonal antibody auristatin conjugates for the treatment of cancer
- 16:45 IS/15 **TM Allen (University of Alberta, Canada)**  
Recent developments in ligand-targeted liposomal drug delivery
- 17:15 Close

POSTER PRESENTATIONS (please see accompanying poster booklet for related posters)

Sunday 3rd August



## Focus Session 2 - Asthma and Inflammatory Pulmonary Diseases

Sponsored by Arriva Pharmaceuticals, Inc

BALLROOM A

Chairs: *W Selig* (Nitromed, USA)  
& *A Payne* (British American Tobacco, UK)

- 14:15 IS/16 **R R Schellenberg** (University of British Columbia, Canada)  
Asthma pathophysiology and remodeling - where might we intervene?
- 14:45 IS/17 **J C Hogg** (University of British Columbia, Canada)  
Small airway inflammation in chronic obstructive pulmonary disease
- 15:15 Refreshments and exhibition (Exhibition Hall B)
- 15:45 2.2 J Hammersley, AL Busza, A White, H Lloyd, M Salmon, D Underwood, R Osborn, D Reid and K Changani  
*Longitudinal characterisation of bleomycin induced pulmonary fibrosis in the rat.*
- 16:00 2.4 HC Atherton, G Jones and H Danahay  
*IL-13 induces a MAPK-dependent increase in goblet cell density (GCD) in human bronchial epithelial cells (HBECS)*
- 16:15 2.5 M Coghlan, J Taylor, M Yeadon and I.C. Kilty  
*Potential anti-inflammatory treatment for asthma and COPD via inhibition of IKK signalosome activity with a small molecule inhibitor, demonstration of whole cell mode of action*



Sunday 3rd August

16:30 2.17 PA Pemberton, JS Cantwell, KM Kim, HL Gibson, KM Connolly, DJ Sundin, WC Abraham, JR Topping, EJ Vanden Bon, RC Tennant, TT Hansel, PJ Barnes, TD Tetley and PJ Barr  
*Multifunctional protease inhibitors for potential treatment of respiratory disease*

16:45 IS/17A **G O'Neill (Merck Frosst Canada)**  
The prostanoid DP receptor as a target of allergic rhinitis

17:15 Close

POSTER PRESENTATIONS (please see accompanying poster booklet for related posters)

### **Focus Session 3: New Aspects of COX-2 Inhibition**

EXHIBITION HALL A

*Chairs: K Seibert (Pharmacia Corporation, USA) and J Evans (Merck Research Labs, USA)*

14:15 IS/18 **II Singer (Merck Research Labs, USA)**  
COX-1 is the major isoform of cyclooxygenase co-localized with prostacyclin synthase in normal dog aortic endothelium.

14:45 **D Simmons (Brigham Young University, USA)**  
Variants of COX isoenzymes: COX-3 and PCOX proteins

15:15 Refreshments and exhibition (Exhibition Hall B)



- 15:45 IS/19 **JL Ellis (Nitromed, USA)**  
NO-Coxibs: a new generation  
of cyclooxygenase-2 inhibitors
- 16:15 3.4 **S A Saeed, S Ahmed, S Pervez  
and A H Gilani**  
*New aspects of cyclooxygenase-  
2 inhibition in myocardial  
infarction and ischaemia*
- 16:30 3.3 **F Grall, X Gu, L Tan, JY Cho, MS Inan,  
A Petit, BK Choy, C Manning,  
L Zerbin, SR Goldring, EM Gravalles,  
P Oettgen, MB Goldring and  
TA Libermann**  
*The epithelial-specific Ets factor ESE-1  
is a novel transcriptional mediator of  
inflammation that regulates COX-2  
expression*
- 16:45 Close

POSTER PRESENTATIONS (please see accompanying poster book-  
let for related posters)

## Focus Session 4 New Visions in Medicinal Chemistry

BALLROOM C

*Chairs: D Roland (Novartis, USA) and V Koatz (Brazil)*

- 14:15 IS/20 **C Dominguez (Amgen, USA)**  
p38 MAP-kinase: an exciting target  
for the treatment of inflammatory  
diseases
- 14:45 IS/21 **DS Garvey (Nitromed, USA)**  
Synthesis and structure-activity-  
relationships of a series of novel  
nitric oxide donor containing  
selective cyclooxygenase-2 inhibitors



Sunday 3rd August

---

- 15:15 Refreshments and exhibition  
(Exhibition Hall B)
- 15:45 IS/22 **R Tommasi (Novartis Pharmaceuticals, USA)**  
Potent, selective and orally  
bioavailable carboxylic acid based  
MMP-13 inhibitors. better than  
hydroxamates?
- 16:15 IS/22A **WK Haggmann (Merck Research Labs, USA)**  
VLA-4 integrin antagonists potential  
treatment of inflammatory diseases
- 16:45 Close

### **Focus Session 5 - Ocular Inflammation: Pathophysiology & Therapy**

MEETING ROOM 8/15

*Chairs: M Stern (Allergan, USA) and SC Pflugfelder  
(Cullen Eye Institute, USA)*

- 14:15 IS/23 **ME Stern (Allergan, USA)**  
The pathophysiology of dry eye - an  
immune-based inflammation
- 14:45 IS/24 **SC Pflugfelder (Cullen Eye Institute, USA)**  
Role of ocular surface inflammation  
in the pathogenesis of  
keratoconjunctivitis sicca
- 15:15 Refreshments and exhibition  
(Exhibition Hall B)
- 15:45 IS/25 **JY Niederkorn (University of Texas, USA)**  
Role of interferon gamma and tumor  
necrosis factor-related apoptosis-  
inducing ligand (TRAIL) in CD4+ T  
cell-dependent rejection of  
intraocular tumors in mice



16:15 IS/26 **JT Rosenbaum** (Casey Eye Institute, USA)  
Using the eye to image the immune response: observations using time-lapse, intravital microscopy

16:45 IS/27 **VL Calder** (Institute of Ophthalmology, UK)  
T cell mechanisms in chronic allergic eye disease (CAED)

17:15 Close

POSTER PRESENTATIONS (please see accompanying booklet for related posters)

## Focus Session 6: Cardiovascular Inflammation

BALLROOM B

*Chairs: B Lucchesi* (University of Michigan Medical School, USA)  
*and P Sirois* (University of Sherbrooke, Canada)

14:15 IS/28 **P Sirois** (University of Sherbrooke, Canada)  
Targeting diabetic hyperalgesia

14:45 IS/29 **BR Lucchesi** (University of Michigan Medical School, USA)  
C-reactive protein and myocardial infarct size after ischemia/reperfusion.

15:15 Refreshments and exhibition  
(Exhibition Hall B)

15:45 IS/30 **WD Campbell** (University of British Columbia, Canada)  
Carboxypeptidase R is an acute phase plasma enzyme that inactivates anaphalatoxins and regulates fibrinolysis

16:15 6.7 MJ Sanz, Y Naim Abu Nabah, T Mateo, R Estelles, J Zagorski, HM Sarau and PJ Jose  
*Angiotensin II induces rapid*



Sunday 3rd August

---

*neutrophil accumulation in rats  
mediated by release of CINC/KC and  
MIP-2*

16:30 IS/30A **T Kurth** (Harvard Medical School, USA)  
NSAIDs inhibit benefits of aspirin on  
first MI

17:00 Close

POSTER PRESENTATIONS (please see accompanying booklet for  
related posters)

### **Teaching Session 1: Classic Animal Models of Inflammation**

MEETING ROOM 12

*Chair: R Carlson (Provident Preclinical Inc, Doylestown, PA, USA)*

14:15 IS/31 **LAB Joosten** (UMC Nijmegen,  
The Netherlands)  
Murine collagen-induced arthritis  
(CIA): the role of antibodies, T-cells  
and pro-inflammatory cytokines  
during development and full blown  
arthritis

15:00 Refreshments and exhibition  
(Exhibition Hall B)

15:30 IS/32 **AM Trocha** (Nitromed, USA)  
Six-day rat carrageenan air-pouch  
model: development and response to  
anti-inflammatory COX-2 selective  
inhibitors.

16:15 IS/33 **RP Carlson** (Provident Preclinical Inc,  
Doylestown, USA)  
Comparison of rat adjuvant arthritis  
(RAA) and streptococcal cell wall  
(SCW) models of induced polyarthritis

17:00 Close



**Special Evening Symposium on COPD**  
*Sponsored by GlaxoSmithKline*

BALLROOM C

*Chairs: J C Hogg (University of British Columbia, Canada),  
& DWP Hay (GlaxoSmithKline, USA)*

- |       |       |  |
|-------|-------|--|
| 19:00 |       | <b>DWP Hay (GlaxoSmithKline, USA)</b><br>Introduction  |
| 19:05 | IS/34 | <b>J C Hogg (University of British Columbia, Canada)</b><br>An overview of chronic obstructive pulmonary disease                         |
| 19:35 |       | <b>N Voelkel (University of Colorado, USA)</b><br>Role of inflammation in COPD   |
| 20:05 | IS/35 | <b>R Pauwels (University Hospital, Ghent, Belgium)</b><br>Treatment of COPD: current and potential novel therapies and future directions |
| 20:35 |       | <b>B Celli (St Elizabeth's Medical Center, USA)</b><br>Clinical evaluation of potential new treatments: what to measure, when and how?   |
| 21:05 |       | Discussion   |



**Monday 4th August**

**Distinguished Mentor Award Lecture**

*Sponsored by Pfizer, Inc*

EXHIBITION HALL A

- 07:50 President of IAIS:  
**W van den Berg** (University Medical Centre, Nijmegen, The Netherlands)  
Introduction
- 08:00 IS/36 **I G Otterness** (USA)  
Looking back and reaching forward

**Plenary Session 2**

EXHIBITION HALL A

*Chairperson: R Dyer (Pfizer, USA)*

- 08:30 IS/37 **M B Grisham**  
(LSU Health Science Centre, USA)  
Divergent roles of nitric oxide and superoxide in post-ischemic liver injury

- 09:15 Poster Session B, Exhibition and coffee break (Exhibition Hall B)

**Symposium 4 - The Role of Cytokines in Inflammation**

*Sponsored by Novartis*

BALLROOM A

*Chair: H Gram (Novartis Pharma, Switzerland)*

- 10:30 IS/38 **I L Campbell** (Scripps Research Institute, USA)  
Interferons in inflammation and tumorigenesis in the brain revealed by dysregulated STAT signaling



- 11:10 **C Hogaboam** (University of Michigan Medical School, USA)  
Targeting IL-13 responsive cells in pulmonary disease
- 11:50 IS/39 **I B McInnes**  
(University of Glasgow, UK)  
Regulating inflammatory synovitis
- 12:30 Lunch, Poster Session B, Exhibition (Exhibition Hall B)  
Lunchtime session (Room 8/15)

## Symposium 5 - Signal Transduction in Inflammation

*Sponsored by Celgene corporation*

### BALLROOM B

*Chairs: A Lewis (Celgene, USA) and S Ghosh (Yale University, USA)*

- 10:30 IS/40 **B L Bennett** (Celgene, USA)  
JNK - a central effector of the cell stress response
- 11:10 IS/40A **S Ghosh** (Yale University, USA)  
NF- $\kappa$ B: a mediator of innate immune responses
- 11:50 **J O'Shea** (NIH, USA)  
Cytokine signaling: basic and clinical implications
- 12:30 Lunch, Poster Session B, Exhibition (Exhibition Hall B)  
Lunchtime session (Room 8/15)



Monday 4th August

---

## Symposium 6 - Fibrosis and Inflammation

BALLROOM C

*Chairs: J Gauldie (McMaster University, Canada)  
& D Schuppan (University of Erlangen-Nuernberg,  
Germany)*

- 10:30 IS/41 **D Schuppan (University of Erlangen-Nuernberg, Germany)**  
Treatment of liver fibrosis: from bench to bedside
- 11:10 **J Gauldie (McMaster University, Canada)**  
Pulmonary Fibrosis: Inflammation, TGF Beta and beyond
- 11:50 **A Eddy (Childrens Hospital and Regional Medical Centre, Seattle, USA)**  
Inflammation and fibrosis in progressive renal disease
- 12:30 Lunch, Poster Session B, Exhibition (Exhibition Hall B)  
Lunchtime Session

### Lunchtime Seminar

*Sponsored by Centocor*

MEETING ROOM 8/15

- 12:40 **M Chevrier (University of Maryland, USA)**  
Immune-mediated inflammatory disorders (I.M.I.D) - the role of Inflammation in I.M.I.D diseases



## Focus Session 7 - Biomarkers and Imaging in Inflammatory Diseases

BALLROOM B

*Chairs: M Shibuya (University of Tokyo, Japan) and  
C Miller (Bio-Imaging Technologies, USA)*

- 14:15 IS/42 **J Pouyssegur (CNRS, France)**  
Hypoxic and non-hypoxic induction mechanisms of HIF-1 $\alpha$
- 14:40 IS/43 **M Shibuya (University of Tokyo, Japan)**  
VEGF-receptor system is involved in arthritis
- 15:05 7.1 SN Desai, MJ Panzenbeck, DM White, KM Crane, ML Brown, CL Cywin and DM Spero  
*An orally active, inhibitor of cathepsin S inhibits human trans vivo DTH.*
- 15:20 Refreshments and exhibition  
(Exhibition Hall B)
- 15:45 7.2 JP Pelletier, JP Raynauld, G Beaudoin, MJ Berthiaume, J DeGuise, DA Bloch, RD Altman, M Hochberg, G Cline, J Meyer and J Martel-Pelletier  
*Menisci damage in knee osteoarthritis (OA) assessed by quantitative MRI testing is predictive of cartilage degradation progression*
- 16:00 IS/44 **CG Miller (Bio-Imaging Technologies Inc, USA)**  
The role of imaging bio-markers in the evaluation of inflammatory disease
- 16:20 IS/44A **SMS Totterman (Virtual Scopics, USA)**  
MR imaging of arthritis



Monday 4th August

- 
- 16:45 7.3 CL Peters, PI Mapp, VR Winrow,  
CE Lewis, DR Blake and CJ Morris  
*Does hypoxia promote proliferative  
synovitis?*
- 17:00 Close
- 18:00 Grouse Mountain experience  
(first coaches depart)

POSTER PRESENTATIONS ( see page accompanying booklet for  
related posters)

### **Focus Session 8 - Gene Targeting in Inflammation**

BALLROOM C

*Chair: W van den Berg (University Medical Center, Nijmegen,  
Netherlands)*

- 14:15 IS/45 **P D Robbins (University of Pittsburgh, USA)**  
Gene and cell based therapies for  
inflammatory diseases
- 14:45 IS/46 **D Curiel (University of Alabama at  
Birmingham, USA)**  
Targeted cancer gene therapy: the  
flexibility of adenoviral gene therapy  
vectors
- 15:15 Refreshments and exhibition  
(Exhibition Hall B)
- 15:45 8.1 C Tan, A Troussard, N Mawji, C Ong,  
A Mui, R St. Arnaud and S Dedhar  
*The effects of conditional knock-out  
of integrin linked kinase on  
macrophage activity*



- 16:00 8.4 LAB Joosten, MI Koenders, M Jacobs, MMA Helsen, E Lubberts, FAJ Van de Loo and WB Van den Berg  
*Critical role of MyD88 adaptor molecule for IL-1/TLR signaling in streptococcal cell wall (SCW) arthritis*
- 16:15 8.5 A Kanthasamy, S Kaul, D Lahiri, V Anantharam and A Kanthasamy  
*Caspase-3 dependent proteolytic activation of PKC $\delta$  regulates NF- $\kappa$ B nuclear translocation in oxidative stress-induced cell death*
- 16:30 8.6 DK Lahiri, D Chen, Y Ge, M Farlow, A Kanthasamy, NH Greig and JT Rogers  
*Role of inflammatory cytokines in the expression of the beta-amyloid precursor protein (APP) in Alzheimer's Disease (AD)*
- 16:45 Close
- 18:00 Grouse Mountain experience  
(first coaches depart)

POSTER PRESENTATIONS (see accompanying booklet for related posters)

## Focus Session 9 - Sports Injury and Inflammation

MEETING ROOM 8/15

Chair: *J Esdaile* (Arthritis Research Centre, Canada)

- 14:15 **C Frank** (University of Calgary, Canada)  
An overview of tendon and ligament injuries and inflammation



Monday 4th August

- 
- 14:45            **D Hart (University of Calgary, Canada)**  
Basic aspects of tendonitis and the  
role of inflammation in tendon and  
ligament healing: a new perspective
- 15:15            Refreshments and exhibition  
(Exhibition Hall B)
- 15:45    IS/46A    **A Banes (University of Carolina, USA)**  
Mechanical loading modulates matrix  
remodeling and MMP expression in  
human bioartificial tendons
- 16:15    IS/47        **K Khan (University of British Columbia,  
Canada)**  
Does 'tendinitis' exist?
- 16:45            Close
- 18:00            Grouse Mountain experience  
(first coaches depart)

## **Focus Session 10 - Skin Inflammation and Wound Healing**

*Sponsored by Arriva Prometic Inc*

MEETING ROOM 11

*Chairs: G Bowen (Onyvax, UK) and Y Miyachi (Kyoto  
University Graduate School of Medicine, Japan)*

- 14:15    IS/49        **K Asadullah (Schering AG, Germany)**  
Interleukin (IL)-10 and psoriasis
- 14:45    IS/48        **N Kambe (Kyoto University Graduate School  
of Medicine, Japan)**  
The roles of human mast cells in  
tissue remodeling
- 15:15            Refreshments and exhibition  
(Exhibition Hall B)



15:45 10.7 JM Daley, JS Reichner, EJ Mahoney,  
L Mansfield, WL Henry Jr,  
B Mastrofrancesco and JE Albina  
*The wound neutrophil: an anti-  
inflammatory cell*

16:00 10.12 D Šveljevic-Jaran, M Veljaca,  
I Glojnaric, M Dominis-Kramaric,  
M Bubenik, S Stipanivic, V Ivetic,  
S Radosevic, V Erakovic and  
MJ Parnham  
*PL 14736 and skin wound healing in  
alloxan diabetic rats*

16:15 Close

18:00 Grouse Mountain experience  
(first coaches depart)

POSTER PRESENTATIONS (see accompanying booklet for related  
posters)

## **Focus Session 11 - NO Containing Drugs: Therapeutic Opportunities**

BALLROOM A

*Chairs: G Letts (Nitromed, USA) and J Wallace (University of  
Calgary, Canada)*

14:15 IS/49A **S Fiorucci (University of Perugia, Italy)**  
Nitric oxide containing drugs -  
therapeutic opportunities

14:45 IS/50 **P Del Soldato (Nicox, France)**  
NO-donating drugs, a novel class of  
very effective and safe compounds of  
potential interest to the  
rheumatologist

15:15 Refreshments and exhibition  
(Exhibition Hall B)



Monday 4th August

- 
- 15:45 11.2 **M Marshall**, JE Keeble and PK Moore  
*Effect of NO-NSAID on vascular reactivity in the endotoxin-treated rat*
- 16:00 11.4 **V Lagente**, E Naline, I Guenon, M Corbel, E Boichot, JL Burgaud, P Del Soldato and C Advenier  
*NCX-950, a nitric-oxide-releasing salbutamol, elicits potent relaxant and anti-inflammatory activities of the airways*
- 16:15 IS/51 **B Jonzon** (Astra Zeneca, Sweden)  
COX-inhibiting nitric oxide donator (CINOD): a new concept in the treatment of pain and inflammation
- 16:45 Close
- 18:00 Grouse Mountain experience (first coaches depart)

POSTER PRESENTATIONS (see accompanying booklet for related posters)

## Focus Session 12 - Eicosanoids and Atherosclerosis

EXHIBITION HALL A

*Chairs: C Brink (CNRS, Paris) and C Serhan (Harvard Medical School, Boston)*

- 14:15 IS/52 **C Brink** (CNRS, Paris)  
Eicosanoid receptors and atherosclerosis
- 14:45 IS/53 **CD Funk** (University of Pennsylvania, USA)  
Lipoxygenases in atherosclerosis
- 15:15 Refreshments and exhibition (Exhibition Hall B)



15:45 IS/54 **CN Serhan** (Harvard Medical School, Boston)  
Novel endogenous anti-inflammatory lipid mediators: resolvins & docosatrienes

16:15 Close

18:00 Grouse Mountain experience  
(first coaches depart)

POSTER PRESENTERS (see accompanying booklet for related posters)

## Teaching Session 2 - Medicinal Chemistry in the Design of New Drugs

MEETING ROOM 12

*Chairs: J Skotnicki (Wyeth Research, USA) and K Koch (Array BioPharma, USA)*

14:15 IS/55 **K Koch** (Array BioPharma, USA)  
New strategies to decrease attrition rates and increase productivity in drug discovery

15:15 Refreshments and exhibition  
(Exhibition Hall B)

15:45 IS/56 **J S Skotnicki** (Wyeth Research, USA)  
Medicinal chemistry strategies for lead optimization

16:45 Close

18:00 Grouse Mountain experience  
(first coaches depart)



**Tuesday 5th August**

---

### **Women In Science Award Lecture**

*Sponsored by GlaxoSmithKline, Pfizer Research and Development and Astra Zeneca*

EXHIBITION HALL A

- 07:50 IAIS Past President:  
**R McMillan (AstraZeneca, UK)**  
Introduction
- 08:00 **S Brain (Kings College London, UK)**  
Polymorphonuclear leukocyte  
accumulation: influence on  
microvascular and nociceptive events

### **Plenary Session 3**

*Sponsored by Millennium Pharmaceuticals, Inc*

EXHIBITION HALL A

*Chair: R Griffiths (Pfizer, Inc)*

- 08:30 **M Weinblatt (Brigham and Women's Hospital, USA)**  
The latest therapies for rheumatoid  
arthritis

- 09:15 Poster Session C, Exhibition and  
coffee break (Exhibition Hall B)

### **Symposium 7 - Lipid Mediators**

EXHIBITION HALL A

*Chairs: S Murota (Japan) and P Borgeat (Laval University, Canada)*

- 10:30 IS/57 **S Narumiya (Kyoto University, Japan)**  
Prostanoids, inflammation, anti-  
inflammation, allergy and immunity



- 11:10 IS/58 **M Pouliot** (Laval University, Canada)  
Biosynthesis of lipoxygenase and cyclooxygenase products in human neutrophils: regulation by adenosine
- 11:50 IS/59 **M Rola-Pleszczynski** (University of Sherbrooke, Canada)  
Regulation of expression of leukotriene receptors by cytokines
- 12:30 Lunch, Poster Session C, Exhibition (Exhibition Hall B)  
Lunchtime session (Room 8 / 15)

## Symposium 8 - Systemic Inflammatory Response Syndrome

Organized by the Brazilian Inflammation Society (BIS)

### BALLROOM A

*Chairs: F Q Cunha* (University of Sao Paolo, Brazil)  
*and R Schultz* (University of Alberta, Canada)

- 10:30 IS/60 **DN Granger** (Louisiana State University, USA)  
Local and distant organ inflammatory responses to ischemia-reperfusion
- 11:00 IS/61 **FQ Cunha** (University of Sao Paolo, Brazil)  
Paradoxical effect of NO on neutrophil function in sepsis
- 11:30 IS/62 **R Schultz** (University of Alberta, Canada)  
Role of matrix metalloproteinases as effectors of pro-inflammatory cytokine stress in the heart
- 12:00 IS/63 **HC Castro-Faria-Neto** (Fundacao Oswaldo Cruz, Brazil)  
Role of PAF-acetylhydrolase in sepsis: potential use for the recombinant enzyme



Tuesday 5th August.

---

12:30 Lunch, Poster Session C, Exhibition  
(Exhibition Hall B)  
Lunchtime session (Room 8/15)

## **Symposium 9 - Histamine and Inflammation**

*Organised by the Hungarian Inflammation Society (HIS)*

BALLROOM B

*Chairs: A Falus (Semmelweis Medical University, Hungary)  
& M Ennis (Queens University of Belfast, UK)*

- 10:30 IS/64 **M Ennis (Queens University, Belfast, UK)**  
Allergy and inflammation: clinical and  
laboratory aspects of histamine  
research
- 11:00 IS/65 **WA Fogel (Polish Academy of Sciences,  
Poland)**  
Histamine metabolism in  
inflammatory diseases
- 11:30 **WP Fung Leung (Johnson & Johnson  
Pharmaceutical Research & Development, USA)**  
H4 receptor in mast cells and  
eosinophils
- 12:00 IS/66A **A Falus (Semmelweis Medical University,  
Hungary)**  
Histamine deficiency in a transgenic  
murine model reveals unknown  
activities for histamine
- 12:30 Lunch, Poster Session C, Exhibition  
(Exhibition Hall B)  
Lunchtime session (Room 8/15)

Tuesday 5th August.



---

## Mini symposium - Resolution of Inflammation

BALLROOM C

*Chairs: T Lawrence (University of California, USA) and A Rossi (University of Edinburgh Medical School, UK)*

- 10:30 IS/69 **C N Serhan (Harvard Medical School, USA)**  
Novel docosanoids and resolvins:  
autacoids in anti-inflammation and  
resolution
- 11:00 IS/71 **MV Sitkovsky (NIH & NIAID, USA)**  
Purinergic control of acute  
inflammatory tissue damage: clinical  
implications
- 11:30 IS/68 **AG Rossi (University of Edinburgh  
Medical School, UK)**  
Selective induction of inflammatory  
cell apoptosis and their augmented  
removal by phagocytes: a double hit  
strategy for therapeutic intervention
- 12:00 IS/70 **C Ward (University of Edinburgh  
Medical School, UK)**  
Resolution of inflammation: the  
regulation of granulocyte apoptosis
- 12:30 IS/67 **T Lawrence (University of California, USA)**  
The NF-kappaB pathway and the  
resolution of inflammation
- 13:00 - 14:15 Lunch, Poster Session C, Exhibition  
(Exhibition Hall B)  
Luncheon Session



Tuesday 5th August.

**Luncheon Seminar:  
New Developments in Leukocyte  
Trafficking**

*Sponsored by Inflazyme Pharmaceuticals / LigoCyte  
Pharmaceuticals*

MEETING ROOM 8/15

*Chair: C Kasserra (Inflazyme Pharmaceuticals, Canada)*

12:45		<b>Robert Bargatze</b> (LigoCyte Pharmaceuticals, USA) Introduction
12:50	Inf/3	<b>CM Doerschuk</b> (Case Western Reserve University, USA) Signaling in pulmonary microvascular endothelial cells initiated by adhesion of neutrophils
13:07	Inf/2	<b>CW Smith</b> (Baylor College of Medicine, USA) Neutrophil transendothelial migration - site selection and kinetics
13:25	Inf/4	<b>AC Issekutz</b> (Dalhousie University, Canada) Adhesion molecules involved in active and T cell transferred adjuvant arthritis (AA) in the rat
13:42	Inf/1	<b>CE Kasserra</b> (Inflazyme Pharmaceuticals, Canada) Novel, small molecule inhibitors of leukocyte trafficking
14:00		Close

Tuesday 5th August.



---

## Focus Session 13 - Functional Genomics

BALLROOM B

*Chairs: S Gilman (Millennium Pharmaceuticals, USA) and  
M Tocci (Aventis Pharmaceuticals, USA)*

- 14:15 IS/72 **R Kapeller (Millennium Pharmaceuticals, USA)**  
Modern alchemy: how to get from gene to function
- 14:45 IS/73 **I Hildebrandt (UCLA School of Medicine, USA)**  
Non-invasive molecular imaging approaches for detecting gene expression in living subjects
- 15:15 Refreshments and exhibition (Exhibition Hall B)
- 15:45 13.1 MG Scott, K Lee, L Hu, S McLean, REW Hancock and BB Finlay  
*Cationic peptides as modulators of immune responses*
- 16:00 IS/74 **PR Griffin (ExSAR Corporation, USA)**  
High throughput analysis of protein ligand interactions using H/D-Ex MS
- 16:30 **M Hemann (Cold Spring Harbor Laboratory, USA)**  
Title to be confirmed
- 19:00 Reception and Congress Dinner, (Fairmont Vancouver Hotel)

POSTER PRESENTATIONS (see accompanying booklet for related posters)



Tuesday 5th August.

---

## Focus Session 14 - Neurogenic Inflammation and Pain

MEETING ROOM 8/15

*Chairs: J Henry (University of Western Ontario, Canada) and M Vasko (Indiana University School of Medicine, USA)*

- 14:15      **M Vasko (Indiana University School of Medicine, USA)**  
Signal transduction pathways augmenting neurotransmitter release from sensory neurons
- 14:45      **J Henry (University of Western Ontario, Canada)**  
Neuropeptides as disease modifiers in neurogenic inflammation
- 15:15      Refreshments and exhibition (Exhibition Hall B)
- 15:45    14.2    S Moochhala, MD Shirhan, C Ker Xing, F Anuar, K Low S Yang and J Lu  
*Mercaptoethylguandine inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions in rats following fluid-percussion brain injury*
- 16:00    14.6    M Pouliot, ME Fiset and C Gilbert  
*Human neutrophils as a source of nociceptin: a novel link between pain and inflammation.*
- 16:15    14.8    C S Patil, N K Jain, A Singh and S K Kulkarni  
*Cholinergic-NO-cGMP Mediation Of Sildenafil- Induced Antinociception*



16:30 14.10 JE Keeble, FA Rocha, NEC Hamilton and SD Brain  
*Novel techniques to evaluate CFA-induced inflammation in the murine knee joint: contribution of microvascular components*

16:45 Concluding Remarks

17:00 Close

19:00 Reception and Congress Dinner  
(Fairmont Vancouver Hotel)

POSTER PRESENTATIONS (see accompanying booklet for related posters)

## Focus Session 15 - Chemokine Antagonists

EXHIBITION HALL A

*Chairs: T Williams (Imperial College, UK) and J Westwick (Novartis, UK)*

14:15 IS/75 **TJ Williams (Imperial College, UK)**  
CCR3 antagonists in the treatment of asthma and allergy

14:45 **J Westwick (Novartis, UK)**  
The role of PI3Kinase gamma in chemokine stimulated cells *in vivo* and *in vitro*

15:15 Refreshments and exhibition  
(Exhibition Hall B)

15:45 15.1 T L Collins, M Johnson, A-R Li, J Liu, A Huang, L Zhu, A Marcus, J Danao, J Smith, L Seitz, K K Berry, J Kumer, C Lawrence, E Sablan and G R Tonn  
*T487: a selective and potent small molecule antagonist of CXCR3.*



Tuesday 5th August.

- 
- 16:00            **J Strizki (Schering Plough, USA)**  
Update on CCR5 antagonists and  
their indications
- 16:30    IS/76    **F Colotta (Dompe SpA, Italy)**  
A new class of non-competitive  
allosteric inhibitors of the  
inflammatory chemokine receptors  
CXCR1 and CXCR2: prevention of  
reperfusion injury.
- 17:00            Close
- 19:00            Reception and Congress Dinner  
(Fairmont Vancouver Hotel)

### **Focus Session 16 - Nutraceuticals, Natural Products and Inflammation**

BALLROOM C

*Chairs: M Miller (Albany Medical College, USA) and  
A Mayer (Midwestern University, USA)*

- 14:15    IS/77    **MJS Miller (Albany Medical College, USA)**  
Natural products from the Amazon  
rainforest: from jungle to bench to  
bedside
- 14:45    IS/78    **RS Jacobs (University of California, USA)**  
The relationship between the natural  
injury protection properties of the  
pseudopterosins to their  
anti-inflammatory properties
- 15:15            Refreshments and exhibition  
(Exhibition Hall B)
- 15:45    16.8    **JP Fuhrer, JC Eley, CA McPhillips,  
RC Stohrer, DA Gingerich and LR Beck**  
*Small molecule mediators of  
inflammation from bovine immune  
milk*



- 16:00 16.15 SC Sampaio, M. Santos, SM Carneiro, EC dos Santos, AC Rangel-Santos, P Brigatte, MCC. Sousa-e-Silva, R Curi and Y Cury  
*Inhibitory effect of crotoxin on macrophage function*
- 16:15 IS/79 **TM Haqqi** (Case Western Reserve University, USA)  
Green tea and the prevention of arthritis
- 16:45 Close
- 19:00 Reception and Conference Dinner  
(Fairmont Vancouver Hotel)

POSTER PRESENTATIONS: (See accompanying booklet for related posters)

## Session 17 - Inflammatory Bowel Disease

Sponsored by AstraZeneca, Sangstat Medical Corporation and Novartis Pharma AG

### MEETING ROOM 11

*Chairs: S Murthy* (Drexel University College of Medicine, USA) & *G Lichtenstein* (University of Pennsylvania School of Medicine, USA)

- 14:15 **G Lichtenstein** (University of Pennsylvania School of Medicine, USA)  
Clinical application of biologic therapy to IBD: state of the art
- 14:45 IS/81 **HD Moore** (Novartis Research Institute, Austria)  
Discovery of novel therapies for inflammatory bowel disease (IBD)
- 15:15 Refreshments and exhibition  
(Exhibition Hall B)



Tuesday 5th August.

- 
- 15:45 17.2 **LP Hale** and **JE Onken**  
*Bromelain treatment alters cytokine and chemokine production by cultured human colon biopsies*
- 16:00 17.3 **R Drouin**, **M-G Gagnon** and **M Purcell**  
*Correction of cytokine imbalance by PureCell Complex (PCT) in an animal model of IBD.*
- 16:15 **BG Feagan** (**University of Western Ontario, Canada**)  
Budesonide in the treatment of Crohn's disease
- 16:45 **RJ Tesi** (**Sangstat Medical Corp, USA**)  
RDP58, a novel cytokine inhibitor, its mechanism of action and role in treating active ulcerative colitis
- 17:15 Close
- 19:00 Reception and Congress dinner  
(*Fairmont Vancouver Hotel*)

POSTER PRESENTATIONS: (See accompanying booklet for related abstracts)

### **Focus Session 18 - Young Investigator Presentations**

*Sponsored by Boehringer Ingelheim, Pfizer Inc and the International Association of Inflammation Societies (IAIS)*

#### **BALLROOM A**

*Chairs: RP Carlson (Provident Preclinical Inc, Doylestown, PA, USA)  
& D Howat (KS Biomedix UK)*

- 14:15 18.3/ **Zoë Johnson** (**Serono Pharmaceutical Research Institute, Geneva**)  
**MP3\***  
A novel strategy for blocking chemokine mediated inflammation



- 14:35 18.2/  
MP2\* **Soraia Costa** (Centre for Cardiovascular  
Biology and Medicine, King's College, Guy's  
Campus, London)  
Activation of 5-HT<sub>4</sub> receptors causes  
neurogenic inflammation in the  
cutaneous microvasculature
- 14:55 18.4/  
MP4\* **Boris Manoury** (INSERM U456, University  
of Rennes, France)  
Deficiency in reactive oxygen species  
in p47<sup>phox</sup><sup>-/-</sup> mice attenuates  
bleomycin-induced pulmonary  
fibrosis
- 15:15 Refreshments & Exhibition  
(Exhibition Hall B)
- 15:45 18.6/  
MP6\* **Ruben Smeets** (Department of  
Experimental Rheumatology and Advanced  
Therapeutics, University Medical Center,  
Nijmegen, The Netherlands)  
Modulation of arthritis through over-  
expression of soluble interleukin-1  
receptor accessory protein (sIL-  
1RAcP); a novel inhibitor of  
interleukin-1, distinct from IL-1RA
- 16:05 18.1/  
MP1\* **Anje Cauwels** (Department for Molecular  
Biomedical Research, Ghent University and  
Flanders Interuniversity Institute, Ghent, Belgium)  
Caspase inhibition causes hyperacute  
tumor necrosis factor-induced shock  
via oxidative stress and phospholipase  
A2
- 16:25 18.5/  
MP5\* **Mark Paul-Clark** (The William Harvey  
Research Institute, Bart's and the London School  
of Medicine and Dentistry, London)  
The enhanced anti-inflammatory  
properties of nitro-prednisolone  
(NCX-1015) is linked to post-  
translational modification of the  
glucocorticoid receptor

\*MP = Mini papers (located at back of abstract book)



Tuesday 5th August.

---

- 16:45 Close
- 19:00 Reception and Conference Dinner  
(Fairmont Vancouver Hotel)

### Teaching Session 3 - Genetic Models of Inflammation for *in vivo* Drug Discovery

MEETING ROOM 12

*Chairs: T Oravec*z (Lexicon Genetics, USA) and  
*AD Luster* (Massachusetts General Hospital, USA)

- 14:15 **A D Luster** (Massachusetts General Hospital, USA)  
Defining chemokine pathways that mediate disease
- 14:45 **K Ley** (University of Virginia Health System, USA)  
Using gene-targeted mice to untangle the web of inflammatory mediators
- 15:15 Refreshments and exhibition  
(Exhibition Hall B)
- 15:45 IS/81A **T Oravec**z (Lexicon Genetics, USA)  
*In vivo* evaluation of inflammatory targets in the post-genom era
- 16:10 **A de Fougerolles** (AInylam Pharmaceuticals USA)  
Cell type dissection of inflammation using knock-out mice and the potential of RNAi
- 16:35 **G Liao** (Roche Palo Alto, USA)  
*In silico* haplotype-based mapping of complex disease-related traits in mice
- 17:00 Close
- 19:00 Reception and Congress dinner  
(Fairmont Vancouver Hotel)

**Wednesday 6th August**



**Symposium 10 - Chemokines and Related Molecules in Inflammation**

*Organised and sponsored by Japanese Society for Inflammation & Regeneration (JSIR)*

BALLROOM A

*Chairs: K Matsushima (University of Tokyo, Japan) and C Gerard (Harvard Medical School, USA)*

- 08:00 **C Gerard (Harvard Medical School, USA)**  
Disease models implicating CXCR3 as an effector cell
- 08:30 **T Schall (Chemocentryx, USA)**  
Novel chemokine receptors including CCR12: new disease targets & therapeutic approaches for orally-active small molecules
- 09:00 IS/82 **T Yokomizo (University of Tokyo, Japan)**  
Leukotriene B<sub>4</sub> receptors: cloning, pharmacology, and functions *in vivo*
- 09:30 IS/83 **KM Matsushima (University of Tokyo, Japan)**  
Regulation by chemokines of the fate of circulating myeloid and plasmacytoid dendritic cell precursors
- 10:00 Coffee (Exhibition Hall A)

**Symposium 11 - Innate Immunity and Inflammation**

*Organised and sponsored by Group de Recherche et d'Etude des Mediators de l'Inflammation (GREMI)*

BALLROOM B

*Chairs: M Chignard (Institute Pasteur, France) & D Golenbock (University of Massachusetts, USA)*



Wednesday 6th August.

- 
- 08:00            **D Golenbock** (University of Massachusetts, USA)  
The innate immune response to bacteria: TLRs meet their ligands
- 08:40    IS/84    **M Si-Tahar** (Institute Pasteur, France)  
Toll-like receptors and lung mucosal immunity
- 09:20    IS/85    **JJ Oppenheim** (National Cancer Institute, USA)  
Defensins and autoantigens interact with G protein coupled receptors
- 10:00            Coffee (Exhibition Hall A)

## **Symposium 12 - Inflammation Pathways in Insulin Resistance - Related Metabolic Diseases**

*Organised and Sponsored by the Inflammation Research Association (IRA)*

BALLROOM C

*Chairs: P Lin (GlaxoSmithKline, USA) and M White (Joslin Diabetes Center USA)*

- 08:00            **M White** (Joslin Diabetes Center, USA)  
IRS proteins and the common path to diabetes
- 08:40    IS/86    **I Jialal** (UC Davis Medical Center, USA)  
Role of inflammation in diabetic vasculopathies
- 09:20    IS/87    **J Corbett** (St Louis University School of Medicine, USA)  
Protection and recovery of pancreatic B-cells from cytokine-mediated damage
- 10:00            Coffee (Exhibition Hall A)



**Special Plenary Session  
Late-Breaking Clinical Data on New  
Anti-Inflammatory Drugs**

EXHIBITION HALL A

*Chairs: J R Kalden (University of Erlangen, Neurnberg, Germany)  
and G Panayi (Guy's Hospital, UK)*

- 10:30      **G Panayi (Guys' Hospital, UK)**  
Rituzamab, an anti-DC20  
monoclonal antibody for the  
treatment of rheumatoid arthritis
- 11:00      **A Kavanaugh (UCSD, La Jolla, USA)**  
CTLA-4-Ig: a novel  
immunomodulatory therapy
- 11:30      **J Naruta (Drexel University College of  
Medicine, USA)**  
Atherosclerosis, inflammation and  
therapeutic advances
- 12:00      **J R Kalden (University of Erlangen,  
Neurnberg, Germany)**  
The use of TNF-blockers in the  
treatment of psoriatic arthritis and  
other orfan rheumatic diseases
- 12:30      **L Marshall**  
Closing remarks
- 12:45      Meeting Close